Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Argos Not Stopping Cancer Vaccine Study Despite Futility

Executive Summary

The biotech suggests that ADAPT trial design was not ideally structured to show the longer-term benefit that might result from its autologous immunotherapy. Argos plans to discuss its plan with FDA in May, despite analyst skepticism.

Advertisement

Related Content

Argos Says FDA Willing To ADAPT To Longer Follow-Up For Immunotherapy
Argos And Agenus Trials Pile On Fresh Cancer Vaccine Disappointments
Argos Nears Phase III Results For Precision Cancer Immunotherapy
Argos passes on IPO and raises $25m Series D to fund personalized cancer immunotherapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel